Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters

Database
Language
Affiliation country
Publication year range
1.
Sci Adv ; 6(12): eaax7945, 2020 03.
Article in English | MEDLINE | ID: mdl-32219156

ABSTRACT

Because of its key role in cancer development and progression, STAT3 has become an attractive target for developing new cancer therapeutics. While several STAT3 inhibitors have progressed to advanced stages of development, their underlying biology and mechanisms of action are often more complex than would be expected from specific binding to STAT3. Here, we have identified and optimized a series of compounds that block STAT3-dependent luciferase expression with nanomolar potency. Unexpectedly, our lead compounds did not bind to cellular STAT3 but to another prominent anticancer drug target, TrxR1. We further identified that TrxR1 inhibition induced Prx2 and STAT3 oxidation, which subsequently blocked STAT3-dependent transcription. Moreover, previously identified inhibitors of STAT3 were also found to inhibit TrxR1, and likewise, established TrxR1 inhibitors block STAT3-dependent transcriptional activity. These results provide new insights into the complexities of STAT3 redox regulation while highlighting a novel mechanism to block aberrant STAT3 signaling in cancer cells.


Subject(s)
Antineoplastic Agents/pharmacology , Enzyme Inhibitors/pharmacology , STAT3 Transcription Factor/antagonists & inhibitors , Thioredoxin Reductase 1/antagonists & inhibitors , Antineoplastic Agents/chemistry , Cell Death/drug effects , Cell Line, Tumor , Dose-Response Relationship, Drug , Enzyme Inhibitors/chemistry , Gene Expression Regulation, Neoplastic/drug effects , Genes, Reporter , Humans , NF-E2-Related Factor 2/agonists , Oxidation-Reduction/drug effects , Oxidative Stress/drug effects , STAT3 Transcription Factor/metabolism , Transcriptional Activation/drug effects
2.
Sci Adv ; 6(1): eaax8358, 2020 01.
Article in English | MEDLINE | ID: mdl-31911946

ABSTRACT

Irreversible oxidation of Cys residues to sulfinic/sulfonic forms typically impairs protein function. We found that persulfidation (CysSSH) protects Cys from irreversible oxidative loss of function by the formation of CysSSO1-3H derivatives that can subsequently be reduced back to native thiols. Reductive reactivation of oxidized persulfides by the thioredoxin system was demonstrated in albumin, Prx2, and PTP1B. In cells, this mechanism protects and regulates key proteins of signaling pathways, including Prx2, PTEN, PTP1B, HSP90, and KEAP1. Using quantitative mass spectrometry, we show that (i) CysSSH and CysSSO3H species are abundant in mouse liver and enzymatically regulated by the glutathione and thioredoxin systems and (ii) deletion of the thioredoxin-related protein TRP14 in mice altered CysSSH levels on a subset of proteins, predicting a role for TRP14 in persulfide signaling. Furthermore, selenium supplementation, polysulfide treatment, or knockdown of TRP14 mediated cellular responses to EGF, suggesting a role for TrxR1/TRP14-regulated oxidative persulfidation in growth factor responsiveness.


Subject(s)
Cysteine/genetics , Oxidation-Reduction/drug effects , Thioredoxin Reductase 1/genetics , Thioredoxins/genetics , Animals , Cysteine/chemistry , Epidermal Growth Factor/genetics , HSP90 Heat-Shock Proteins/genetics , Homeodomain Proteins/chemistry , Homeodomain Proteins/genetics , Humans , Kelch-Like ECH-Associated Protein 1/genetics , Mice , PTEN Phosphohydrolase/genetics , Protein Tyrosine Phosphatase, Non-Receptor Type 1/genetics , Selenium/pharmacology , Signal Transduction/drug effects , Sulfides/metabolism , Sulfides/pharmacology , Thioredoxin Reductase 1/chemistry , Thioredoxins/chemistry
SELECTION OF CITATIONS
SEARCH DETAIL